CN101098860A - 芳基嘧啶基化合物、含有它们的药物组合物及其作为抗微生物剂的应用 - Google Patents

芳基嘧啶基化合物、含有它们的药物组合物及其作为抗微生物剂的应用 Download PDF

Info

Publication number
CN101098860A
CN101098860A CNA2005800460269A CN200580046026A CN101098860A CN 101098860 A CN101098860 A CN 101098860A CN A2005800460269 A CNA2005800460269 A CN A2005800460269A CN 200580046026 A CN200580046026 A CN 200580046026A CN 101098860 A CN101098860 A CN 101098860A
Authority
CN
China
Prior art keywords
alkyl
cooh
arom
molecule
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800460269A
Other languages
English (en)
Chinese (zh)
Inventor
H·米尼耶-莱曼
D·古盖
G·拉贝斯
S·波谢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CN101098860A publication Critical patent/CN101098860A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800460269A 2004-11-05 2005-11-04 芳基嘧啶基化合物、含有它们的药物组合物及其作为抗微生物剂的应用 Pending CN101098860A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292629A EP1655288A1 (en) 2004-11-05 2004-11-05 Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
EP04292629.5 2004-11-05

Publications (1)

Publication Number Publication Date
CN101098860A true CN101098860A (zh) 2008-01-02

Family

ID=34931507

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800460269A Pending CN101098860A (zh) 2004-11-05 2005-11-04 芳基嘧啶基化合物、含有它们的药物组合物及其作为抗微生物剂的应用

Country Status (7)

Country Link
US (1) US20080096907A1 (enExample)
EP (2) EP1655288A1 (enExample)
JP (1) JP2008519001A (enExample)
CN (1) CN101098860A (enExample)
BR (1) BRPI0517646A (enExample)
CA (1) CA2586073A1 (enExample)
WO (1) WO2006048336A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476411A (zh) * 2010-11-29 2013-12-25 法玛科技顾问股份有限公司 标靶人类胸腺核苷酸激酶诱导恶性肿瘤中的dna修复毒性

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2475482C1 (ru) * 2012-01-13 2013-02-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный университет" Комплексное соединение 5-гидрокси-6-метилурацила с сукцинатом натрия и способ его получения
CA3018611C (en) * 2016-03-22 2024-02-27 Glaxosmithkline Intellectual Property Development Limited Antituberculosis agent
US20220041627A1 (en) * 2018-12-04 2022-02-10 University Of Maryland, Baltimore Prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1959705A1 (de) * 1969-11-28 1971-06-03 Bayer Ag Verfahren zur Herstellung von Uracilderivaten
JPH08325238A (ja) * 1995-05-30 1996-12-10 Asahi Glass Co Ltd ５−トリフルオロメチルウラシル誘導体およびその製造方法
ATE201016T1 (de) * 1995-06-09 2001-05-15 Hoffmann La Roche Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
EP1255738B1 (en) * 2000-01-25 2012-03-07 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
JP4542311B2 (ja) * 2001-01-29 2010-09-15 バイオ−ラッド ラボラトリーズ インコーポレイテッド 核酸誘導体
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476411A (zh) * 2010-11-29 2013-12-25 法玛科技顾问股份有限公司 标靶人类胸腺核苷酸激酶诱导恶性肿瘤中的dna修复毒性

Also Published As

Publication number Publication date
BRPI0517646A (pt) 2008-10-14
US20080096907A1 (en) 2008-04-24
CA2586073A1 (en) 2006-05-11
JP2008519001A (ja) 2008-06-05
EP1814867A2 (en) 2007-08-08
WO2006048336B1 (en) 2006-11-09
WO2006048336A2 (en) 2006-05-11
WO2006048336A3 (en) 2006-10-12
EP1655288A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
DE69511253T2 (de) Wasserlösliche 3-arylidene-2-oxindole derivate als tyrosine kinase inhibitoren
Gasse et al. Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: Synthesis and in vitro anti-mycobacterial activity
Wigerinck et al. 5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication
CN100513398C (zh) 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
TWI496774B (zh) 作為ｃｄｋ抑制劑之經亞碸亞胺取代的苯胺嘧啶衍生物，其製造及其作為醫藥品之用途
CH620925A5 (enExample)
JPS63132889A (ja) キナゾリノン誘導体
Balzarini et al. Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine
CA2184754A1 (fr) Derives de 5h-indeno[1,2-b]pyrazine-2,3-dione, leur preparation et les medicaments les contenant
LU84316A1 (fr) Nouvelles thiazolidinediones,leur procede de production et preparation pharmaceutique les contenant
DE69734246T2 (de) Sysntheseverfahren zur herstellung von indolylquinonen und mono- und bis-indolylquinone, die durch das verfahren hergestellt sind
EP3169684B1 (en) Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders
NL8303311A (nl) Piperazinederivaten met anti-cholinergische en/of anti-histamineactiviteit.
JP2001247550A (ja) 縮合環化合物及びその医薬用途
CN101098860A (zh) 芳基嘧啶基化合物、含有它们的药物组合物及其作为抗微生物剂的应用
CA2217026C (en) New antiviral substituted pyrimidinedione homocarbocyclic nucleoside derivatives and methods for the preparation thereof and compositions containing the same as active ingredients
Kelley et al. Pyrimidine acyclic nucleosides. 5-Substituted 1-[(2-aminoethoxy) methyl] uracils as candidate antivirals
CN102186817B (zh) (羟烷基)吡咯衍生物的阻转异构体
JPH0643421B2 (ja) ピリミジン誘導体
FR2493702A1 (fr) Compositions antivirales contenant des derives d'acide aminosulfonylhalogenobenzoique
EP3820847B1 (en) Improved compounds for myc inhibition
EP0120770B1 (fr) Dérivés de 2-aminoéthyl pyridine ou pyrazine, leur préparation et les compositions pharmaceutiques les contenant
JPH0629264B2 (ja) ２‐アミノ‐５‐ヒドロキシ‐４‐ピリミドン
WO2009153514A1 (fr) Phenyl-alkyl piperazines ayant une activite modulatrice du tnf
JPH0812694A (ja) ホスフィン酸誘導体、その調製方法およびその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080102